Selected research
Industry Research
Retinal Drugs and Biologics Industry Research Report 2026
Market perspective
The global Retinal Drugs and Biologics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Retinal Drugs and Biologics is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Retinal Drugs and Biologics is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Retinal Drugs and Biologics is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Retinal Drugs and Biologics include ALLERGAN, Alimera Sciences, Bausch & Lomb, Bristol-Myers Squibb, Genentech, Genzyme, Janssen Biotech, OCULAR THERAPEUTIX and Swedish Orphan Biovitrum, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Retinal Drugs and Biologics market in terms of revenue (US$ million) and, where applicable, sales volume (k tons), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k tons) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Retinal Drugs and Biologics Market by Company
ALLERGAN
Alimera Sciences
Bausch & Lomb
Bristol-Myers Squibb
Genentech
Genzyme
Janssen Biotech
OCULAR THERAPEUTIX
Swedish Orphan Biovitrum
UCBCares
AbbVie
Roche
Retinal Drugs and Biologics Segment by Type
Ocular Inflammatory Disease (Uveitis)
Diabetic Retinopathy
Age Related Macular Degeneration
Macular Hole
Retinal Drugs and Biologics Segment by Application
Hospitals
Clinics
Others
Retinal Drugs and Biologics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Retinal Drugs and Biologics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Retinal Drugs and Biologics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Retinal Drugs and Biologics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Retinal Drugs and Biologics manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Retinal Drugs and Biologics by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Retinal Drugs and Biologics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ocular Inflammatory Disease (Uveitis)
- Diabetic Retinopathy
- Age Related Macular Degeneration
- Macular Hole
Applications
- Hospitals
- Clinics
- Others
Companies covered
- ALLERGAN
- Alimera Sciences
- Bausch & Lomb
- Bristol-Myers Squibb
- Genentech
- Genzyme
- Janssen Biotech
- OCULAR THERAPEUTIX
- Swedish Orphan Biovitrum
- UCBCares
- AbbVie
- Roche
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Retinal Drugs and Biologics Market Size (2021-2032)
- 2.2.2 Global Retinal Drugs and Biologics Sales (2021-2032)
- 2.2.3 Global Retinal Drugs and Biologics Market Average Price (2021-2032)
- 2.3 Retinal Drugs and Biologics by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ocular Inflammatory Disease (Uveitis)
- 2.3.3 Diabetic Retinopathy
- 2.3.4 Age Related Macular Degeneration
- 2.3.5 Macular Hole
- 2.4 Retinal Drugs and Biologics by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Clinics
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Retinal Drugs and Biologics Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Retinal Drugs and Biologics Sales (k tons) of Manufacturers (2021-2026)
- 3.3 Global Retinal Drugs and Biologics Revenue of Manufacturers (2021-2026)
- 3.4 Global Retinal Drugs and Biologics Average Price by Manufacturers (2021-2026)
- 3.5 Global Retinal Drugs and Biologics Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Retinal Drugs and Biologics, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Retinal Drugs and Biologics, Product Type & Application
- 3.8 Global Manufacturers of Retinal Drugs and Biologics, Established Date
- 3.9 Global Retinal Drugs and Biologics Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 ALLERGAN
- 4.1.1 ALLERGAN Company Information
- 4.1.2 ALLERGAN Business Overview
- 4.1.3 ALLERGAN Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 ALLERGAN Retinal Drugs and Biologics Product Portfolio
- 4.1.5 ALLERGAN Recent Developments
- 4.2 Alimera Sciences
- 4.2.1 Alimera Sciences Company Information
- 4.2.2 Alimera Sciences Business Overview
- 4.2.3 Alimera Sciences Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Alimera Sciences Retinal Drugs and Biologics Product Portfolio
- 4.2.5 Alimera Sciences Recent Developments
- 4.3 Bausch & Lomb
- 4.3.1 Bausch & Lomb Company Information
- 4.3.2 Bausch & Lomb Business Overview
- 4.3.3 Bausch & Lomb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bausch & Lomb Retinal Drugs and Biologics Product Portfolio
- 4.3.5 Bausch & Lomb Recent Developments
- 4.4 Bristol-Myers Squibb
- 4.4.1 Bristol-Myers Squibb Company Information
- 4.4.2 Bristol-Myers Squibb Business Overview
- 4.4.3 Bristol-Myers Squibb Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bristol-Myers Squibb Retinal Drugs and Biologics Product Portfolio
- 4.4.5 Bristol-Myers Squibb Recent Developments
- 4.5 Genentech
- 4.5.1 Genentech Company Information
- 4.5.2 Genentech Business Overview
- 4.5.3 Genentech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Genentech Retinal Drugs and Biologics Product Portfolio
- 4.5.5 Genentech Recent Developments
- 4.6 Genzyme
- 4.6.1 Genzyme Company Information
- 4.6.2 Genzyme Business Overview
- 4.6.3 Genzyme Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Genzyme Retinal Drugs and Biologics Product Portfolio
- 4.6.5 Genzyme Recent Developments
- 4.7 Janssen Biotech
- 4.7.1 Janssen Biotech Company Information
- 4.7.2 Janssen Biotech Business Overview
- 4.7.3 Janssen Biotech Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Janssen Biotech Retinal Drugs and Biologics Product Portfolio
- 4.7.5 Janssen Biotech Recent Developments
- 4.8 OCULAR THERAPEUTIX
- 4.8.1 OCULAR THERAPEUTIX Company Information
- 4.8.2 OCULAR THERAPEUTIX Business Overview
- 4.8.3 OCULAR THERAPEUTIX Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 OCULAR THERAPEUTIX Retinal Drugs and Biologics Product Portfolio
- 4.8.5 OCULAR THERAPEUTIX Recent Developments
- 4.9 Swedish Orphan Biovitrum
- 4.9.1 Swedish Orphan Biovitrum Company Information
- 4.9.2 Swedish Orphan Biovitrum Business Overview
- 4.9.3 Swedish Orphan Biovitrum Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Swedish Orphan Biovitrum Retinal Drugs and Biologics Product Portfolio
- 4.9.5 Swedish Orphan Biovitrum Recent Developments
- 4.10 UCBCares
- 4.10.1 UCBCares Company Information
- 4.10.2 UCBCares Business Overview
- 4.10.3 UCBCares Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 UCBCares Retinal Drugs and Biologics Product Portfolio
- 4.10.5 UCBCares Recent Developments
- 4.11 AbbVie
- 4.11.1 AbbVie Company Information
- 4.11.2 AbbVie Business Overview
- 4.11.3 AbbVie Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 AbbVie Retinal Drugs and Biologics Product Portfolio
- 4.11.5 AbbVie Recent Developments
- 4.12 Roche
- 4.12.1 Roche Company Information
- 4.12.2 Roche Business Overview
- 4.12.3 Roche Retinal Drugs and Biologics Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Roche Retinal Drugs and Biologics Product Portfolio
- 4.12.5 Roche Recent Developments
5 Global Retinal Drugs and Biologics Market Scenario by Region
- 5.1 Global Retinal Drugs and Biologics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Retinal Drugs and Biologics Sales by Region: 2021-2032
- 5.2.1 Global Retinal Drugs and Biologics Sales by Region: 2021-2026
- 5.2.2 Global Retinal Drugs and Biologics Sales by Region: 2027-2032
- 5.3 Global Retinal Drugs and Biologics Revenue by Region: 2021-2032
- 5.3.1 Global Retinal Drugs and Biologics Revenue by Region: 2021-2026
- 5.3.2 Global Retinal Drugs and Biologics Revenue by Region: 2027-2032
- 5.4 North America Retinal Drugs and Biologics Market Facts & Figures by Country
- 5.4.1 North America Retinal Drugs and Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Retinal Drugs and Biologics Sales by Country (2021-2032)
- 5.4.3 North America Retinal Drugs and Biologics Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Retinal Drugs and Biologics Market Facts & Figures by Country
- 5.5.1 Europe Retinal Drugs and Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Retinal Drugs and Biologics Sales by Country (2021-2032)
- 5.5.3 Europe Retinal Drugs and Biologics Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Retinal Drugs and Biologics Market Facts & Figures by Country
- 5.6.1 Asia Pacific Retinal Drugs and Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Retinal Drugs and Biologics Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Retinal Drugs and Biologics Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Retinal Drugs and Biologics Market Facts & Figures by Country
- 5.7.1 South America Retinal Drugs and Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Retinal Drugs and Biologics Sales by Country (2021-2032)
- 5.7.3 South America Retinal Drugs and Biologics Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Retinal Drugs and Biologics Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Retinal Drugs and Biologics Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Retinal Drugs and Biologics Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Retinal Drugs and Biologics Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Retinal Drugs and Biologics Sales by Type (2021-2032)
- 6.1.1 Global Retinal Drugs and Biologics Sales by Type (2021-2032) & (k tons)
- 6.1.2 Global Retinal Drugs and Biologics Sales Market Share by Type (2021-2032)
- 6.2 Global Retinal Drugs and Biologics Revenue by Type (2021-2032)
- 6.2.1 Global Retinal Drugs and Biologics Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Retinal Drugs and Biologics Revenue Market Share by Type (2021-2032)
- 6.3 Global Retinal Drugs and Biologics Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Retinal Drugs and Biologics Sales by Application (2021-2032)
- 7.1.1 Global Retinal Drugs and Biologics Sales by Application (2021-2032) & (k tons)
- 7.1.2 Global Retinal Drugs and Biologics Sales Market Share by Application (2021-2032)
- 7.2 Global Retinal Drugs and Biologics Revenue by Application (2021-2032)
- 7.2.1 Global Retinal Drugs and Biologics Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Retinal Drugs and Biologics Revenue Market Share by Application (2021-2032)
- 7.3 Global Retinal Drugs and Biologics Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Retinal Drugs and Biologics Value Chain Analysis
- 8.1.1 Retinal Drugs and Biologics Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Retinal Drugs and Biologics Production Mode & Process
- 8.2 Retinal Drugs and Biologics Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Retinal Drugs and Biologics Distributors
- 8.2.3 Retinal Drugs and Biologics Customers
9 Global Retinal Drugs and Biologics Analyzing Market Dynamics
- 9.1 Retinal Drugs and Biologics Industry Trends
- 9.2 Retinal Drugs and Biologics Industry Drivers
- 9.3 Retinal Drugs and Biologics Industry Opportunities and Challenges
- 9.4 Retinal Drugs and Biologics Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst